What are the 2026 sepsis guidelines and what is MALDI‑TOF (matrix‑assisted laser desorption ionization time‑of‑flight mass spectrometry) in sepsis?

2026 Sepsis Guidelines and MALDI-TOF in Sepsis

Important Clarification

There are no published 2026 sepsis guidelines available. The most recent major international sepsis guidelines are the Surviving Sepsis Campaign 2016 guidelines (published 2017) 1. A 2025 update of the German S3 sepsis guidelines was published in July 2025, which adapted the Surviving Sepsis Campaign 2021 recommendations 2, 3.

Current Sepsis Guidelines (2016/2025)

Core Immediate Management Principles

Sepsis and septic shock are medical emergencies requiring immediate treatment 1. The algorithmic approach is:

Within First Hour:

• Administer IV antimicrobials within 1 hour of recognition for both sepsis and septic shock (strong recommendation, moderate evidence) 1
• Obtain at least 2 sets of blood cultures (aerobic and anaerobic) before antibiotics, but do not delay antimicrobials >45 minutes 1, 4
• Give minimum 30 mL/kg IV crystalloid fluid within first 3 hours (strong recommendation, low evidence) 1

Initial Resuscitation Targets:

• Target MAP ≥65 mmHg as initial goal (strong recommendation, moderate evidence) 1
• Norepinephrine is first-choice vasopressor to maintain MAP (strong recommendation) 5
• Consider higher MAP targets (70-80 mmHg) in patients with chronic hypertension showing clinical improvement with higher pressures 6
• Normalize lactate as marker of tissue hypoperfusion (weak recommendation, low evidence) 1

Antimicrobial Strategy:

• Empiric broad-spectrum therapy covering all likely pathogens including bacterial, fungal, or viral (strong recommendation, moderate evidence) 1
• De-escalate within first few days once pathogen identified or clinical improvement noted 1
• Duration: 7-10 days adequate for most serious infections (weak recommendation, low evidence) 1
• Daily assessment for de-escalation is mandatory 1

---

MALDI-TOF in Sepsis

MALDI-TOF MS (Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry) is a rapid diagnostic technology that identifies bacteria and fungi directly from positive blood cultures, dramatically accelerating pathogen identification compared to conventional methods.

Clinical Impact

MALDI-TOF MS reduces time-to-pathogen identification by 1.36-1.47 days compared to conventional culture methods (2-5 days vs. 1.47 days, p=0.0052) 7. This translates to:

• 48% reduction in identification time 7
• Enables earlier targeted antimicrobial therapy 8
• Improved clinical response rates (88.5% vs. 73.2% with traditional methods, p=0.013) 8

Performance Characteristics

For monomicrobial blood cultures:

• 100% genus-level identification for both gram-positive and gram-negative organisms 9
• Species-level identification: 67.7% for gram-positive, 91.4% for gram-negative organisms 9
• Significantly better performance with gram-negative organisms (p<0.0001) 9

Limitations and Pitfalls

Common failure scenarios:

• 25.2% of positive blood cultures yield spectral scores <1.700 (no identification), particularly affecting gram-positive organisms (31.6%) and polymicrobial cultures (32.3%) 9
• Misidentification risk: Streptococcus oralis/mitis can be misidentified as S. pneumoniae 9
• Polymicrobial infections remain challenging with current protocols 10

Optimal Implementation Protocol

The diagnostic algorithm integrating MALDI-TOF MS:

1. Obtain blood cultures before antibiotics (but don't delay antimicrobials) 1
2. Perform Gram stain immediately when blood culture flags positive 9
3. Apply MALDI-TOF MS directly from positive blood culture using standardized extraction protocols 11
4. Alternative rapid protocol: Short-term (5-hour) incubation on solid medium achieves 85% species-level identification, balancing speed with accuracy 12
5. Integrate with antimicrobial stewardship programs through active communication (phone/text to providers or pharmacists) for immediate therapy optimization 11, 8

Clinical Integration Requirements

MALDI-TOF MS effectiveness requires:

• Twice-daily blood culture review by stewardship teams improves time to clinical response (hazard ratio 1.388,95% CI 1.004-1.919) 8
• Multidisciplinary working groups to rapidly apply identification data to clinical management 10
• Standardized processing protocols (still evolving, particularly for gram-positive cocci) 10
• Combination with resistance detection methods since MALDI-TOF MS alone doesn't provide susceptibility data 10

Evidence Quality Note

The American Society for Microbiology published evidence-based guidelines in 2025 supporting rapid diagnostic tests (including MALDI-TOF MS) for improving time-to-targeted therapy, hospital length of stay, and mortality in BSIs, provided active communication occurs 11. This represents the highest-quality guideline evidence specifically addressing MALDI-TOF MS in bloodstream infections.